Literature DB >> 24828779

Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies.

Steven J Simmons1, Thomas J Gould.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Tobacco smoking remains a major health problem. Nicotine binds to nicotinic acetylcholine receptors (nAChRs), which can cause addiction and withdrawal symptoms upon cessation of nicotine administration. Pharmacotherapies for nicotine addiction target brain alterations that underlie withdrawal symptoms. This review will delineate the involvement of the β2 subunit of neuronal nAChRs in nicotine reward and in generating withdrawal symptoms to better understand the efficacy of smoking cessation pharmacotherapies. COMMENT: Chronic nicotine desensitizes and upregulates β2 subunit-containing nAChRs, and the prolonged upregulation of receptors may underlie symptoms of withdrawal. Experimental research has demonstrated that the β2 subunit of neuronal nAChRs is necessary for generating nicotine reward and withdrawal symptoms. WHAT IS NEW AND
CONCLUSION: Smoking cessation pharmacotherapies act on β2 subunit-containing nAChRs to reduce nicotine reward and withdrawal symptom severity.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  nicotine reward; nicotine withdrawal; nicotinic acetylcholine receptor; smoking cessation; β2 subunit

Mesh：

Substances：

Year:  2014        PMID： 24828779      PMCID： PMC4459499          DOI： 10.1111/jcpt.12171

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN： 0269-4727            Impact factor:   2.512


  182 in total

1.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

2.  Craving is associated with smoking relapse: findings from three prospective studies.

Authors:  J D Killen; S P Fortmann
Journal:  Exp Clin Psychopharmacol       Date:  1997-05       Impact factor: 3.157

3.  Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task.

Authors:  S F Logue; R Paylor; J M Wehner
Journal:  Behav Neurosci       Date:  1997-02       Impact factor: 1.912

4.  Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain.

Authors:  M E Benwell; D J Balfour; J M Anderson
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

Review 5.  Neuropsychiatric adverse events of varenicline: a systematic review of published reports.

Authors:  Amir I A Ahmed; Abdullah N A Ali; Cees Kramers; Linda V D Härmark; David M Burger; Willem M A Verhoeven
Journal:  J Clin Psychopharmacol       Date:  2013-02       Impact factor: 3.153

6.  Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area.

Authors:  Christelle Reperant; Stéphanie Pons; Eric Dufour; Hans Rollema; Alain M Gardier; Uwe Maskos
Journal:  Neuropharmacology       Date:  2009-11-01       Impact factor: 5.250

7.  Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning.

Authors:  George S Portugal; Thomas J Gould
Journal:  Pharmacol Biochem Behav       Date:  2007-08-23       Impact factor: 3.533

8.  Current cigarette smoking among adults - United States, 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-11-09       Impact factor: 17.586

9.  Effects of varenicline on abstinence and smoking reward following a programmed lapse.

Authors:  Erin A McClure; Ryan G Vandrey; Matthew W Johnson; Maxine L Stitzer
Journal:  Nicotine Tob Res       Date:  2012-05-09       Impact factor: 4.244

10.  Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice.

Authors:  John Stapleton; Robert West; Peter Hajek; Jenny Wheeler; Eleni Vangeli; Zeinab Abdi; Colin O'Gara; Hayden McRobbie; Kirsty Humphrey; Rachel Ali; John Strang; Gay Sutherland
Journal:  Addiction       Date:  2013-08-28       Impact factor: 6.526
View more
  6 in total

1.  Effects of ceftriaxone on conditioned nicotine reward in rats.

Authors:  Helene L Philogene-Khalid; Steven J Simmons; John W Muschamp; Scott M Rawls
Journal:  Behav Pharmacol       Date:  2017-09       Impact factor: 2.293

2.  Nicotinic receptor blockade decreases fos immunoreactivity within orexin/hypocretin-expressing neurons of nicotine-exposed rats.

Authors:  Steven J Simmons; Taylor A Gentile; Lili Mo; Fionya H Tran; Sisi Ma; John W Muschamp
Journal:  Behav Brain Res       Date:  2016-08-01       Impact factor: 3.332

3.  α2-Null mutant mice have altered levels of neuronal activity in restricted midbrain and limbic brain regions during nicotine withdrawal as demonstrated by cfos expression.

Authors:  Montana Upton; Shahrdad Lotfipour
Journal:  Biochem Pharmacol       Date:  2015-06-22       Impact factor: 5.858

4.  Wheel running during chronic nicotine exposure is protective against mecamylamine-precipitated withdrawal and up-regulates hippocampal α7 nACh receptors in mice.

Authors:  Helen Keyworth; Polymnia Georgiou; Panos Zanos; André Veloso Rueda; Ying Chen; Ian Kitchen; Rosana Camarini; Mark Cropley; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2017-12-22       Impact factor: 8.739

5.  Increased Risky Choice and Reduced CHRNB2 Expression in Adult Male Rats Exposed to Nicotine Vapor.

Authors:  Priscilla Giner; Liliana Maynez-Anchondo; Anna E Liley; Kevin P Uribe; Gabriel A Frietze; Nicholas W Simon; Ian A Mendez
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 6.208

6.  Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder.

Authors:  Amanda M Palmer; Benjamin A Toll; Matthew J Carpenter; Eric C Donny; Dorothy K Hatsukami; Alana M Rojewski; Tracy T Smith; Mehmet Sofuoglu; Johannes Thrul; Neal L Benowitz
Journal:  Nicotine Tob Res       Date:  2022-01-01       Impact factor: 5.825
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.